Information Provided By:
Fly News Breaks for February 25, 2020
GILD, TAK, IOVA
Feb 25, 2020 | 14:46 EDT
Stifel analyst Benjamin Burnett notes that Iovance (IOVA) is trading up as a result of a Bloomberg notice that said the company is exploring a sale. The analyst does not know if this is true but does think this is one of the few cell therapy companies in his coverage with data that has been de-risked to a large degree by a proof-of-concept study. From that standpoint, Burnett can see how this might be one of the more interesting cell therapy takeout candidates. However, the analyst has also speculated in the past that the cell therapy M&A thesis is tough to get behind just because this type of acquisition is not likely to be a tuck-in to most buyers. Burnett adds that both Takeda (TAK) and Gilead (GILD) have demonstrated with past deals that they are interested in cell therapy. Because of Kymriah, Novartis (NVS) also comes to mind as a potential buyer, he contends. He reiterates a Buy rating on Iovance's shares, with an unchanged $35 price target.
News For IOVA;TAK;GILD From the Last 2 Days
GILD
Oct 29, 2020 | 17:23 EDT
Stocks had a positive day after the U. S... To see the rest of the story go to thefly.com. See Story Here
GILD
Oct 29, 2020 | 13:10 EDT
The major averages are higher at midday following a busy morning of earnings updates as well as a GDP report that showed a strong bounce back from the equally sharp contraction seen in the prior quarter. The Nasdaq is... To see the rest of the story go to thefly.com. See Story Here
GILD
Oct 29, 2020 | 09:12 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly.  HIGHER - Inphi... To see the rest of the story go to thefly.com. See Story Here
GILD
Oct 28, 2020 | 19:01 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
GILD
Oct 28, 2020 | 16:03 EDT
The COVID-19 pandemic continues to impact Gilead's business and broader market dynamics, including HCV and PrEP market volume. Gilead expects its core business will continue to gradually recover in the fourth quarter 2020 and into the first half of 2021. Gilead expects that the company's HIV treatment business will continue to remain largely unaffected and that by the first quarter of 2021, patients with HCV will begin to initiate treatment. The acquisition of Immunomedics will immediately contribute to Gilead's revenue growth and is expected to be neutral to accretive to Gilead's non-GAAP EPS in 2023 and significantly accretive thereafter. The fundamentals of Gilead's business and long-term outlook remain strong.
GILD
Oct 28, 2020 | 16:03 EDT
Consensus $6.98. Narrows FY20 product sales view to $23B-$23.5B from $23B-$25B.
GILD
Oct 28, 2020 | 13:05 EDT
Notable companies reporting after the market close, with earnings consensus, include Visa (V), consensus $1.10... Amgen (AMGN), consensus $3.80... ServiceNow (NOW), consensus $1.03... Gilead Sciences (GILD), consensus $1.95... Cognizant Technology (CTSH), consensus 90c... eBay Inc. (EBAY), consensus 86c... O'Reilly Automotive (ORLY), consensus $6.19... Ford Motor (F), consensus 16c... Pinterest (PINS), consensus 2c... Yum China (YUMC), consensus 49c... Cerner (CERN), consensus 71c... Teladoc Health (TDOC), consensus (32c)... Etsy (ETSY), consensus 58c... Livongo Health (LVGO), consensus 5c... Western Digital (WDC), consensus 54c... United Rentals (URI), consensus $4.28... Molina Healthcare (MOH), consensus $2.16... Fastly (FSLY), consensus 0c... SunPower (SPWR), consensus (5c)... Sprouts Farmers Market (SFM), consensus 36c... Sunnova Energy (NOVA), consensus (15c)... Rent-A-Center (RCII), consensus 96c... Spirit Airlines (SAVE), consensus ($2.72).
GILD
Oct 28, 2020 | 06:28 EDT
UBS analyst Colin Bristow initiated coverage of Gilead with a Neutral rating and $61 price target. The analyst says the near-term sentiment on the stock will be driven by filgotinib and remdesivir. He sees the first facing an overhang until safety data are reported in the first half of 2021 and sees the second as having been "well telegraphed" with uncertainty regarding its revenue durability in COVID.